Get the Stockscreener App
37.08
0.35%
-0.13
After Hours:
36.89
-0.19
-0.51%
Viking Therapeutics Inc stock is traded at $37.08, with a volume of 2.46M.
It is down -0.35% in the last 24 hours and down -9.07% over the past month.
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.
See More
Previous Close:
$37.21
Open:
$37.06
24h Volume:
2.46M
Relative Volume:
0.57
Market Cap:
$4.19B
Revenue:
-
Net Income/Loss:
$-99.15M
P/E Ratio:
-39.87
EPS:
-0.93
Net Cash Flow:
$-74.25M
1W Performance:
-3.81%
1M Performance:
-9.07%
6M Performance:
+29.74%
1Y Performance:
-22.54%
1-Day Range:
$36.51
$38.50
1-Week Range:
$36.25
$39.08
52-Week Range:
$18.92
$48.55
Viking Therapeutics Inc Stock (VKTX) Company Profile
Name
Viking Therapeutics Inc
Sector
Industry
Phone
858-704-4660
Address
9920 PACIFIC HEIGHTS BLVD, SUITE 350, SAN DIEGO, CA
Compare VKTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VKTX
Viking Therapeutics Inc
|
37.08 | 4.21B | 0 | -99.15M | -74.25M | -0.93 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Viking Therapeutics Inc Stock (VKTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-29-25 | Initiated | Canaccord Genuity | Buy |
| Apr-29-25 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-08-25 | Initiated | Goldman | Neutral |
| Feb-13-25 | Initiated | Scotiabank | Sector Outperform |
| Feb-07-25 | Initiated | Citigroup | Neutral |
| Dec-02-24 | Initiated | Piper Sandler | Overweight |
| Nov-22-24 | Initiated | B. Riley Securities | Buy |
| Nov-04-24 | Reiterated | H.C. Wainwright | Buy |
| Sep-11-24 | Initiated | JP Morgan | Overweight |
| Jun-27-24 | Initiated | Morgan Stanley | Overweight |
| May-16-24 | Upgrade | Raymond James | Outperform → Strong Buy |
| Mar-26-24 | Reiterated | Oppenheimer | Outperform |
| Mar-07-24 | Initiated | Jefferies | Buy |
| Feb-28-24 | Reiterated | Oppenheimer | Outperform |
| May-31-23 | Resumed | ROTH MKM | Buy |
| Mar-28-23 | Reiterated | Maxim Group | Buy |
| Mar-17-23 | Initiated | Stifel | Buy |
| Jul-29-21 | Resumed | BTIG Research | Buy |
| May-25-21 | Downgrade | Raymond James | Strong Buy → Outperform |
| Jun-05-20 | Initiated | BMO Capital Markets | Outperform |
| May-05-20 | Initiated | Chardan Capital Markets | Buy |
| May-01-20 | Initiated | BTIG Research | Buy |
| Jul-16-19 | Initiated | Oppenheimer | Outperform |
| Jun-25-19 | Initiated | Stifel | Buy |
| Mar-29-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Mar-14-19 | Reiterated | Maxim Group | Buy |
| Feb-22-19 | Initiated | SVB Leerink | Mkt Perform |
| Dec-12-18 | Initiated | B. Riley FBR | Buy |
| Nov-19-18 | Upgrade | Raymond James | Outperform → Strong Buy |
| Sep-18-18 | Reiterated | H.C. Wainwright | Buy |
| Sep-18-18 | Reiterated | Maxim Group | Buy |
| Sep-18-18 | Reiterated | Raymond James | Outperform |
| Jul-20-18 | Initiated | SunTrust | Buy |
| Jun-28-18 | Initiated | Raymond James | Outperform |
| Jun-01-18 | Reiterated | Laidlaw | Buy |
| May-31-18 | Reiterated | Maxim Group | Buy |
| Mar-26-18 | Resumed | H.C. Wainwright | Buy |
| Nov-28-17 | Reiterated | Maxim Group | Buy |
| Nov-21-17 | Initiated | ROTH Capital | Buy |
View All
Viking Therapeutics Inc Stock (VKTX) Latest News
2 Reasons I Wouldn't Touch BioAge Labs Stock With a 10-Foot Pole - The Motley Fool
BlackBarn Capital Partners LP Purchases New Holdings in Viking Therapeutics, Inc. $VKTX - MarketBeat
683 Capital Management LLC Trims Stock Position in Viking Therapeutics, Inc. $VKTX - MarketBeat
Behavioral Patterns of VKTX and Institutional Flows - news.stocktradersdaily.com
Is Early VANQUISH-1 Completion And VK2735 Progress Altering The Investment Case For Viking Therapeutics (VKTX)? - simplywall.st
Frontier Capital Management Co. LLC Increases Stock Holdings in Viking Therapeutics, Inc. $VKTX - MarketBeat
This is why Viking Therapeutics, Inc. (VKTX) is a Strong Buy on Wall Street - Yahoo Finance
3 Underrated Growth Stocks That Look Like Great Buys Heading Into 2026 - Finviz
Unusual Bullish Options Activity Could Be A Game Changer For Viking Therapeutics (VKTX) - Yahoo Finance
Diadema Partners LP Increases Stock Holdings in Viking Therapeutics, Inc. $VKTX - MarketBeat
Viking Therapeutics Faces Pressure as Rival Obesity Drug Data Emerges - Ad-hoc-news.de
Major Investors Pile Into Viking Therapeutics Stock - Ad-hoc-news.de
Looking At Viking Therapeutics's Recent Unusual Options Activity - Benzinga
460,415 Shares in Viking Therapeutics, Inc. $VKTX Acquired by Jump Financial LLC - MarketBeat
Franklin Resources Inc. Has $703,000 Stock Holdings in Viking Therapeutics, Inc. $VKTX - MarketBeat
Viking Therapeutics (VKTX): Valuation Check After Faster-Than-Expected Enrollment in Key Obesity Drug Trial - simplywall.st
Norges Bank Takes $46.85 Million Position in Viking Therapeutics, Inc. $VKTX - MarketBeat
VKTX Stock Forecast 2025–2026: Can Viking Therapeutics’ Obesity Drug Pipeline Really Double the Share Price? - ts2.tech
Viking Therapeutics: Analysts Project Stock Could More Than Double - AD HOC NEWS
Viking Therapeutics Stock: Prepping For A Critical 2026 (NASDAQ:VKTX) - Seeking Alpha
Viking Therapeutics (NASDAQ:VKTX) Shares Up 9.4%Here's Why - MarketBeat
Schroder Investment Management Group Buys 150,470 Shares of Viking Therapeutics, Inc. $VKTX - MarketBeat
Will Viking Therapeutics Inc. stock outperform Nasdaq index2025 AllTime Highs & Verified Chart Pattern Trade Signals - Newser
Will Viking Therapeutics Inc. stock outperform international peersEarnings Overview Summary & Low Volatility Stock Suggestions - Newser
What's Up With The Jump In Viking Therapeutics Stock?Viking Therapeutics (NASDAQ:VKTX) - Benzinga
The FDA Is Shaking Things Up; Biotech, Research Stocks Diverge - Investor's Business Daily
How Viking Therapeutics Inc. (1VT) stock expands through international marketsTrade Ideas & Weekly Breakout Opportunity Watchlist - Newser
What consensus target says about Viking Therapeutics Inc. (1VT) stockMarket Performance Summary & Daily Entry Point Alerts - Newser
Will Viking Therapeutics Inc. stock benefit from sector rotationJuly 2025 Big Picture & Low Drawdown Trading Techniques - Newser
How Viking Therapeutics Inc. stock responds to policy changesBuy Signal & Growth Oriented Trade Recommendations - Newser
Viking Therapeutics Stock Gains Momentum on Clinical Progress - AD HOC NEWS
42,134 Shares in Viking Therapeutics, Inc. $VKTX Purchased by Scotia Capital Inc. - MarketBeat
Why Viking Therapeutics Inc. stock appeals to analysts2025 Pullback Review & Stock Portfolio Risk Management - Newser
Will Viking Therapeutics Inc. (1VT) stock deliver compounding returnsJuly 2025 Setups & Expert Curated Trade Setups - Newser
What margin trends mean for Viking Therapeutics Inc. stockEntry Point & Fast Moving Market Watchlists - Newser
Is There a Future for Viking Therapeutics? - AOL.com
The Bull Case For Viking Therapeutics (VKTX) Could Change Following Early Completion and Positive Data in Obesity Trial - simplywall.st
Viking Therapeutics Emerges as a Prime Acquisition Candidate Amid Obesity Drug Advancements - AD HOC NEWS
XTX Topco Ltd Acquires Shares of 36,199 Viking Therapeutics, Inc. $VKTX - MarketBeat
Viking Therapeutics, Inc. (VKTX) Options Chain - Yahoo! Finance Canada
Why Viking Therapeutics Inc. (1VT) stock attracts HNW investorsQuarterly Trade Report & Proven Capital Preservation Methods - Newser
VKTX Stock Rises 34% in Three Months: Here's What You Should Know - sharewise.com
Viking Therapeutics (VKTX) VANQUISH-1 Trial Completes Early, H.C. Wainwright Retains Buy Rating - MSN
Viking Therapeutics Emerges as a Prime Acquisition Target Following Trial Success - AD HOC NEWS
(VKTX) Movement Within Algorithmic Entry Frameworks - news.stocktradersdaily.com
Viking Therapeutics Stock Gains Momentum on Clinical Trial Milestone - Ad-hoc-news.de
Assessing Viking Therapeutics (VKTX) Valuation After Recent Share Price Recovery - Yahoo Finance
Ensign Peak Advisors Inc Trims Stake in Viking Therapeutics, Inc. $VKTX - MarketBeat
Viking Therapeutics (VKTX): Evaluating Valuation After Key Phase 3 Obesity Trial Milestone and New Clinical Data - Sahm
Viking Therapeutics: A Clash of Convictions - Ad-hoc-news.de
SG Americas Securities LLC Makes New $379,000 Investment in Viking Therapeutics, Inc. $VKTX - MarketBeat
Viking Therapeutics Inc Stock (VKTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Viking Therapeutics Inc Stock (VKTX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Rowland Charles A Jr | Director |
Oct 27 '25 |
Sale |
35.57 |
60,000 |
2,134,278 |
30,000 |
| Lian Brian | President & CEO |
Oct 28 '25 |
Sale |
35.01 |
38,989 |
1,364,923 |
2,419,109 |
| ZANTE GREG | Chief Financial Officer |
Oct 28 '25 |
Sale |
35.00 |
6,185 |
216,481 |
173,592 |
1.08%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):